Inotropic agents in the treatment of heart failure: Despair or hope?

Cardiovascular Drugs and Therapy

Volumn 10, Issue 6, 1997, Pages 703-709

  Sasayama, Shigetake ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Beta receptor; Cyclic AMP; Cytokines; Immunomodulation; Intracellular Ca2+; Phosphodiesterase inhibitor; Survival

Indexed keywords

CALCIUM SENSITIZER; CARDIOTONIC AGENT; CYCLIC AMP; DIGITALIS; IMMUNOMODULATING AGENT; INOTROPIC AGENT; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIPERANOMETOZINE;

HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-AGONISTS; CARDIOTONIC AGENTS; CYCLIC AMP; DIGITALIS; HEART FAILURE, CONGESTIVE; HUMANS; PLANTS, MEDICINAL; PLANTS, TOXIC; PROGNOSIS; PYRIDAZINES; QUINOLINES;

EID: 0030941970     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00053027     Document Type: Review

References (70)

1. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993;22(Suppl A):6A-13A.
2. Harigaya S, Schwartz A. Rate of calcium binding and up-take in normal animal and failing human cardiac muscle. Circ Res 1969;25:781-794.
3. Feldman MD, Copelas L, Gwathmey JK, et al. Deficient production of cyclic AMP: Pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987;75:331-339.
4. Packer M. The development of positive inotropic agents for chronic heart failure: How have we gone astray? J Am Coll Cardiol 1993;22(Suppl A):119A-126A.
5. Sasayama S. What do the newer inotropic drugs have to offer? Cardiovasc Drugs Ther 1992;6:15-18.
6. Armstrong PW, Moe GW. Medical advances in the treatment of congestive heart failure. Circulation 1994;88: 2941-2952.
7. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 1982;307:205-211.
8. Lambertz H, Meyer J, Erbel R. Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation 1984;69:298-305.
9. Dies F, Krell MJ, Whitlow P, Liang CS, Goldenberg I, Applefeld MM, Gilbert EM. Intermittent dobutamine in ambulatory outpatients with chronic heart failure. Circulation 1986;74(Suppl II):II38.
10. Sasayama S, Yokawa S, Akiyama M, Mikawa M, Sakai O. Cardiovascular effects of ICI 118,587, a new beta-adrenoceptor partial agonist in man. Jpn Circ J 1986;50: 636-643.
11. Pouleur H, van Eyll C, Hanet C, Cheron P, Charlier AA, Rousseau MF. Long-term effects of xamoterol on left ventricular diastolic function and late remodeling: A study in patients with anterior myocardial infarction and single-vessel disease. Circulation 1988;77:1081-1089.
12. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6.
13. Benotti JR, Grossman W, Braunwald E, Davolos DD, Alousi AA. Hemodynamic assessment of amrinone. N Engl J Med 1978;299:1373-1377.
14. Packer M, Medina N, Yushak H. Hemodynamic and clinical limitation of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation 1984; 70:1038-1047.
15. Petein M, Levine B, Cohn JN. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure. Circulation 1986;73(Suppl III):III230-III236.
16. Uretsky BF, for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 1990;82:774-780.
17. Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, Likoff M, Packer M, for the Amrinone Multicenter Trial Group. Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial. Circulation 1985;71:963-971.
18. DiBianco R, for the Amrinone Multicenter Study Investigators. Oral amrinone for the treatment of chronic congestive heart failure: Results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol 1984;4:855-866.
19. Packer M, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
20. Colucci WS, for the Milrinone Multicenter Trials Investigators. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. J Am Coll Cardiol 1993; 22(Suppl A):113A-118A.
21. Anversa P, Olivetti G, Melissari M, Loud AV. Stereological measurement of cellular and subcellular hypertrophy and hyperplasia in the papillary muscle of adult rat. J Mol Cell Cardiol 1980;12:781-795.
22. Bashore TM, Magorien DJ, Letterio J, Shaffer P, Unverferth DV. Histologic and biochemical correlates of left ventricular chamber dynamics in man. J Am Coll Cardiol 1987; 9:734-742.
23. Ingwall JS. Is cardiac failure a consequence of decreased energy reserve? Circulation 1993;87(Suppl VII):VII58-VII62.
24. Schultheiss HP, Schulze K, Schauer R, et al. Antibody-mediated imbalance of myocardial energy metabolism. A causal factor of cardiac failure? Circ Res 1995;76:64-72.
25. Katz AM. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 1986; 73(Suppl III):III184-III190.
26. Katz AM. Scientific insights from clinical studies of converting-enzyme inhibitors in the failing heart. Trends Cardiovasc Med 1995;5:37-44.
27. Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: Implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 1992;19:1622-1633.
28. Matsuda H, Noma A, Kurachi Y, Irisawa H. Transient depolarizations and spontaneous voltage fluctuations in isolated single cells from guinea pig ventricles. Circ Res 1982; 51:142-151.
29. Gheorghiade M, Beller GA. Effects of discontinuing maintenance digoxin therapy in patients with ischemic heart disease and congestive heart failure in sinus rhythm. Am J Cardiol 1983;51:1243-1250.
30. Fleg JL, Gottlieb SH, Lakatta EG. Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. Am J Med 1982;73:244-250.
31. Poole-Wilson PA, Robinson K. Digoxin - A redundant drug in congestive cardiac failure. Cardiovasc Drugs Ther 1989; 2:733-741.
32. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle ME. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: Direct evidence from sympathetic neural recordings. Circulation 1989;80:65-77.
33. Covit AB, Schaer GL, Sealey JE, Laragh JH, Cody RJ. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am. J Med 1983; 75:445-447.
34. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259: 539-544.
35. The German and Austrian Xamoterol Study Group. Double blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 1988;1:489-493.
36. DiBianco R, for the Milrinone Multicenter Trial Group. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-683.
37. Packer M, for the RADIANCE Study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993;329:1-7.
38. Krum H, Bigger JT, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995;25: 289-294.
39. Yusuf S, Garg R, Held P, Gorlin R. Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure. Am J Cardiol 1992;69:64G-70G.
40. Gorlin R. The effect of digitalis on mortality and hospitalations in patients with heart failure. Presentation of the 45th Annual Scientific Session of the American College of Cardiology, Orlando, Florida, 1996.
41. Sasayama S, Inoue M, Asanoi H, Kodama K, Hori M, Sakurai T, Kawai C. Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure. Heart Vessels 1986;2:23-28.
42. Iijima T, Taira N. Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. J Pharmacol Exp Ther 1987;240:657-662.
43. Sasayama S, for OPC-8212 Multicenter Research Group. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther 1990;4:19-25.
44. Feldman AM, for the Vesnarinone Study Group. Effects of vesnarinone of morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-155.
45. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. J Clin Invest 1994; 94:1212-1217.
46. Lin CS, Boltz RC, Blake JT, et al. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J Exp Med 1993;177: 637-645.
47. + currents in cytotoxic T lymphocytes. Circ Res 1996;78:253-261.
48. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.
49. Barry WH. Mechanisms of immune-mediated myocyte injury. Circulation 1994;89:2421-2432.
50. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:561-566.
51. Doyama K, Fujiwara H, Fukumoto M, et al. Tumor necrosis factor is expressed in cardiac tissues of patients with heart failure. Int J Cardiol 1996;54:217-225.
52. Yamada T, Matsumori A, Sasayama S. Therapeutic effect of anti-tumor necrosis factor-α antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 1994;89:846-851.
53. Shioi T, Matsumori A, Matsui S, Sasayama S. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sci 1994;54:PL11-16.
54. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994;89:955-958.
55. Matsui S, Matsumori A, Sasayama S. Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. Life Sci 1994;55:1735-1741.
56. Sato Y, Matsumori A, Sasayama S. Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. J Mol Cell Cardiol 1995;27:2265-2273.
57. Hattori Y, So S, Hattori S, Kasai K, Shimoda S. Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture. Cardiovasc Res 1995;30:187-192.
58. Sasayama S. Immune modulation of cardiac function: A new frontier. J Card Failure 1995;1:331-335.
59. Sasayama S, Matsumori A. Role of cytokines in the syndrome of heart failure. Intern Med 1996;35:60-63.
60. Ruegg JC, Morano I. Calcium-sensitivity modulation of cardiac myofibrillar proteins. J Cardiovasc Pharmacol 1989; 14(Suppl III):S20-S23.
61. 2+ activation and the inotropic effect of pimobendan: Comparison with milrinone. Cire Res 1988;63:911-922.
62. Solaro RJ, Fujino K, Sperelakis N. The positive inotropic effect of pimobendan involves stereospecific increases in the calcium sensitivity of cardiac myofilaments. J Cardiovasc Pharmacol 1989;14(Suppl 2):S7-S12.
63. Holubarsch C, Hasenfuss G, Just H, Blanchard E, Mulieri LA, Alpert NR. Influence of the positive inotropic substance pimobendan (UD-CG 115 BS) on contractile economy of guinea pig papillary muscles. J Cardiovasc Pharmacol 1989;14(Suppl II):S13-S17.
64. Hasenfuss G, Holubarsch C, Heiss HW, Rattert B, Just H. Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside. Basic Res Cardiol 1989;84(Suppl I):225-233.
65. Kubo SH, for the Pimobendan Multicenter Research Group. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: Results of a multicenter trial. Circulation 1992;85:942-949.
66. Sasayama S, Asanoi H, Kihara Y, et al. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 1994;9: 113-120.
67. van Meel JCA, Mauz ABM, Wienen W, Biederen W. Pimobendan increases survival of cardiomyopathic hamsters. J Cardiovasc Pharmacol 1989;13:508-509.
68. Verdouw PD, Hartog JM, Duncker DJ, Roth W, Saxena PR. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 1986;126:21-30.
69. Arnout J, Deckmyn H, Huybrechts E, Verstraete M. UDCG 115 and 212, two benzimidazo-pyridazinones with broad spectrum antiplatelet activity. Thromb Haemost 1986;54:134.
70. Just H. For the Pimobendan in Congestive Heart Failure (PICO) Investigators: Effect of pimobendan on exercise capacity in patients with heart failure: main results from the PICO trial. Heart 1996;76:223-231.